연구동향 분석

Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem

변지영 김영훈 김세형 이충민 정의현 채원기 장춘곤 이석용 이윤정 2018년

논문상세정보
    • 저자 변지영 김영훈 김세형 이충민 정의현 채원기 장춘곤 이석용 이윤정
    • 제어번호 105918073
    • 학술지명 Archives of Pharmacal Research
    • 권호사항 Vol. 41 No. 8 [ 2018 ]
    • 발행처 대한약학회
    • 발행처 URL http://www.psk.or.kr
    • 자료유형 학술저널
    • 수록면 861-866 ( 6쪽)
    • 언어 English
    • 출판년도 2018
    • 등재정보 KCI등재
    • 소장기관 부산대학교 중앙도서관 숙명여자대학교 중앙도서관 중앙대학교 서울캠퍼스 중앙도서관 중앙대학교 서울캠퍼스 중앙도서관 중앙대학교 서울캠퍼스 중앙도서관
    • 판매처
    유사주제 논문( 0)
인용/피인용

' Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem' 의 참고문헌

  • Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia
    Holm KJ [2000]
  • Zolpidem: a review of its use in the management of insomnia
  • Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia
    Hoehns J [1993]
  • Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
    Langtry HD [1990]
  • Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations
  • Zolpidem for insomnia
  • The safety and tolerability of zolpidem-an update
    Darcourt G [1999]
  • The pharmacology and mechanism of action of zolpidem
    Sanger DJ [1998]
  • The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
  • The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
    Gorski JC [1998]
  • Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype
    Choi CI [2012]
  • Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals
    Lee HI [2014]
  • Polymorphism of human cytochrome P450 enzymes and its clinical impact
    Zhou SF [2009]
  • Oxidative metabolism of zolpidem by human liver cytochrome P450S
    Pichard L [1995]
  • Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences
  • Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
  • Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes
    Langer SZ [1988]
  • Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
  • Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
    Bae JW [2011]
  • Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites
    변지영 [2015]
  • Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam
    Choi CI [2011]
  • Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174
    Bae JW [2012]
  • Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam
    Bae JW [2011]
  • Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
  • Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite
  • Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites
    김미정 [2018]
  • Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics
    Perrault G [1990]
  • Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application
    Byeon JY [2015]
  • Clinical significance of the cytochrome P450 2C19 genetic polymorphism
    Desta Z [2002]
  • CYP3A4 and CYP2C19 genetic polymorphisms and zolpidem metabolism in the Chinese Han population: a pilot study
    Shen M [2013]
  • CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
    Choi CI [2012]
  • Biaxin (clarithromycin) prescribing information
  • Adverse reactions to zolpidem: case reports and a review of the literature
    Inagaki T [2010]
  • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    Sim SC [2006]